Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Clinical Therapeutics

Failure of Short-Course Ceftriaxone Chemotherapy for Multidrug-Resistant Typhoid Fever in Children: a Randomized Controlled Trial in Pakistan

Zulfiqar A. Bhutta, Iqtidar A. Khan, Mamoon Shadmani
Zulfiqar A. Bhutta
Department of Paediatrics, The Aga Khan University, Karachi, Pakistan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Iqtidar A. Khan
Department of Paediatrics, The Aga Khan University, Karachi, Pakistan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mamoon Shadmani
Department of Paediatrics, The Aga Khan University, Karachi, Pakistan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.44.2.450-452.2000
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

The precise duration of therapy of multidrug-resistant (MDR) typhoid with broad-spectrum cephalosporins is uncertain. We prospectively randomized 57 children with culture-proven MDR typhoid to receive treatment with intravenous ceftriaxone (CRO) (65 mg/kg of body weight/day) for 7 days (short course; n = 29) or 14 days (conventional; n = 28). The response to therapy, as evaluated by the serial monitoring of the typhoid morbidity score and bacteriological clearance, was comparable between groups. In contrast to the conventional therapy, 14% of the children receiving CRO for 7 days had a confirmed bacteriological relapse within 4 weeks of stopping therapy.

Typhoid fever is widely prevalent in developing countries, with an annual burden of 16 million cases globally (16). The emergence of drug-resistant strains in recent years, especially multidrug-resistant (MDR) Salmonella typhi (resistant to ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole), has been of major concern (21). Given the considerable morbidity associated with MDR typhoid in children (5) and increased mortality with delay in treatment (6), it is imperative that appropriate antibiotic therapy be instituted promptly. Oral quinolones have provided an effective oral form of therapy for MDR typhoid in adults but are still not licensed for widespread pediatric use. Where the generic use of quinolones has become widespread, there are also recent disturbing reports of emerging quinolone resistance (9, 25). Broad-spectrum cephalosporins have thus remained an important therapeutic alternative for the therapy of MDR typhoid in children, with excellent primary cure rates (11, 12, 19). We have previously described successful cures of MDR typhoid in hospitalized children receiving therapy with intravenous (i.v.) ceftriaxone (CRO) for 14 days (3, 7); the children were evaluated in accordance with recommendations for the evaluation of anti-infective agents for treating typhoid (10). However, the cost of therapy with a 14-day course of CRO is considerable, frequently beyond the capacity of health care budgets (7). Several studies have therefore explored the potential of shorter courses of CRO for treating typhoid, ranging from 3 to 7 days, with impressive cure rates (1, 11, 14, 17, 22), but only a few such studies (1, 11, 22) have involved patients, especially children, with MDR typhoid.

In order to evaluate a shorter course of therapy with CRO, we designed a prospective randomized controlled trial of either 7 or 14 days of CRO treatment for children admitted with culture-proven MDR typhoid, with an objective evaluation of clinical and microbiological responses to therapy. The sample size of the study (28 patients per treatment group) was determined based on the assumption of a 50% reduction in the cost of therapy for a 7-day course; the cost of therapy for a 14-day course of CRO is Rs.6400 (US$280) (20). Comparative data on baseline characteristics and respective outcomes were evaluated by analysis of variance or chi-square test (with the Yates correction), as required.

For all patients with suspected typhoid, a complete blood count, blood culture, malarial film, and Widal test and liver function test results were obtained. For those who had received previous antibiotic therapy for ≥72 h, a bone marrow culture was also obtained. Five milliliters of blood or bone marrow was inoculated into two blood culture bottles, each containing either brain heart infusion broth or thioglycolate broth. The cultures were examined thereafter for growth at different stages and then subcultured, and positive colonies were identified biochemically with API 20E strips (Analytab Products, Plainview, N.Y.). The sensitivity to respective antibiotics was determined by the Kirby-Bauer disk diffusion method (2).

The protocol of this study was approved by the Human Subjects Protection Committee at The Aga Khan University Medical Center (AKUMC). All children with suspected typhoid fever presenting to the ambulatory care services at AKUMC who were ill enough to require hospitalization were potentially eligible for the study. After giving informed written consent, children with proven MDR typhoid were allocated to either 7- or 14-day therapy with once daily i.v. CRO (65 mg/kg of body weight/day) by a block randomization method that used sealed envelopes. A previously validated composite score of clinical features, i.e., the typhoid morbidity score (TMS), was used to objectively assess response to therapy (3, 4) (Table 1). This score was evaluated for all patients at admission and daily thereafter until completion of the protocol. In all cases, repeat blood cultures were obtained at days 3 and 7 or thereafter as clinically indicated. A blood sample was also obtained among those considered a “clinical failure” of therapy, which was defined as the persistence of fever along with a <2-point reduction in TMS by day 7 of therapy, whereas the persistence of S. typhi in cultures obtained at day 3 or thereafter was considered a “bacteriological treatment failure.” Relapse was defined as the recurrence of fever along with a positive blood culture for S. typhi with a similar antibiogram to the original infecting strain within 8 weeks of the completion of therapy. Given the low yield of urine cultures at follow-up (8) and our previous experience of poor sensitivity among stool cultures from children with typhoid in Karachi (5), no attempt was made to screen the urine or stool cultures of the patients after discharge.

View this table:
  • View inline
  • View popup
Table 1.

Characteristics for determining typhoid morbidity scorea

Of 118 consecutive children with suspected typhoid who were admitted to AKUMC, an alternative diagnosis was established within 48 h of admission for 87 of them. For an additional 19 patients, the S. typhi specimen isolated from them was sensitive to first-line antibiotics, and they were thus placed on appropriate antibiotics. For five additional children, although the cultures were negative, there was supportive serological evidence of typhoid on a Widal test. The patients with presumed typhoid fever were placed on oral amoxicillin for 14 days, and all recovered. In all, 57 children had MDR S. typhi specimens isolated from blood and/or bone marrow cultures and were randomized to either 7- or 14-day therapy with i.v. CRO. All isolates of MDR S. typhi were fully resistant to disk diffusion testing to ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole and were fully sensitive to CRO. Table2 details the admission, clinical, and laboratory characteristics of the two study groups, as well as the respective outcomes. The responses to therapy for both treatment groups were comparable, and although three children were still febrile by the end of the stipulated course of therapy, there were no primary bacteriological treatment failures. In all cases of relapse, a S. typhi specimen with a similar antibiogram to the original isolate was identified from blood cultures. All patients who relapsed were treated with i.v. aztreonam and recovered uneventfully.

View this table:
  • View inline
  • View popup
Table 2.

Comparative clinical and laboratory characteristics of therapy groups

Our data suggest that despite comparable bacteriological and clinical cure rates, a 7-day course of therapy with CRO was associated with a significantly higher rate of relapse in children hospitalized with MDR typhoid, in comparison with a 14-day course of treatment. These data are at variance with information from other studies of short-course therapy with CRO for adults and children with typhoid. However, despite adequate documentation of a cure, few of the latter studies had an adequate follow-up period and did not address the issue of relapse. In addition, most studies of short-course therapy with CRO have been for infections caused by sensitive strains of S. typhi. In Vietnam, where there was an overall 63% incidence of MDR typhoid, Smith et al. observed a 28% primary treatment failure for a 3-day course of CRO therapy (22). In contrast, a 95% cure rate was seen among children with MDR typhoid in Egypt who were randomly selected to receive a 5-day course of CRO (11). In the latter study, Girgis et al. (11) also observed that the time-to-defervescence with CRO was only 3.9 days, which was considerably shorter than the observed pattern of defervescence for MDR typhoid in other parts of Asia (1, 7, 14, 15). It is thus possible that these differences in response to therapy may represent differences in the virulence and antibiotic responsiveness of different strains of S. typhi. Recent data from Asia also underscore the considerable genetic diversity among isolates of S. typhi (23). It is therefore imperative that therapeutic strategies for treating MDR typhoid in children must take local epidemiological patterns and strain specificities into account.

Members of our group (4, 6) and others (18) have previously highlighted the higher toxicity and morbidity of MDR typhoid among children in south Asia. Our data provide additional evidence that a 7-day course of therapy with CRO was associated with a significantly higher and unacceptable relapse rate in Pakistani children with MDR typhoid, in comparison with concurrent controls. This relapse rate was also significantly higher than that observed previously among children from the same center with MDR typhoid who were treated with CRO for 14 days (3, 7, 19). The reasons for the observed high relapse rate after 7 days of therapy with CRO are uncertain. Although the clinical response and bacteriological clearance rates during the period of hospitalization were comparable for both groups, it is possible that a 7-day course was inadequate in clearing S. typhi from the macrophages within the reticuloendothelial system, thereby provoking a relapse. It is also possible that in contrast with sensitive strains ofS. typhi, MDR isolates are more virulent, with comparatively greater involvement of the reticuloendothelial system. This is supported by recent data from Vietnam, which describes increased quantitative bacteremia in cases of MDR typhoid and is suggestive of increased virulence of infective MDR strains of S. typhi(24). Some support for this contention can be also seen from a previous study of MDR typhoid in Karachi (4) correlating high circulating levels of interleukin-6 at admission with correspondingly higher relapse rates. We would therefore urge considerable caution in treating MDR typhoid with i.v. CRO for ≤7 days. It is uncertain if an intermediate course of therapy, one between 7 and 14 days, would be adequate for treating MDR typhoid, and further studies are needed to explore this issue.

ACKNOWLEDGMENTS

This work was supported by an unrestricted research grant from Roche Pharmaceuticals Ltd. (Basel) Switzerland.

FOOTNOTES

    • Received 1 February 1999.
    • Returned for modification 31 July 1999.
    • Accepted 5 November 1999.
  • Copyright © 2000 American Society for Microbiology

REFERENCES

  1. 1.↵
    1. Acharya G.,
    2. Butler T.,
    3. Ho M.,
    4. Sharma P. R.,
    5. Tiwari M.,
    6. Adhikari R. K.,
    7. Khagda J. B.,
    8. Pokhrel B.,
    9. Pathak U. N.
    Treatment of typhoid fever: randomized trial of a three-day course of ceftriaxone versus a fourteen-day course of chloramphenicol. Am. J. Trop. Med. Hyg. 52 1995 162 165
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Bauer A. W.,
    2. Kirby W. M. M.,
    3. Sherris J. C.,
    4. Turck M.
    Antibiotic susceptibility testing by a standardized single disk method. Am. J. Clin. Pathol. 45 1966 493 496
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Bhutta Z. A.,
    2. Khan I. A.,
    3. Molla A. M.
    Therapy of multidrug-resistant typhoid fever with oral cefixime vs intravenous ceftriaxone. Pediatr. Infect. Dis. J. 13 1994 990 994
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Bhutta Z. A.,
    2. Mansoorali N.,
    3. Hussain R.
    Plasma cytokines in paediatric typhoidal salmonellosis: correlation with clinical course and outcome. J. Infect. 35 1997 253 256
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Bhutta Z. A.,
    2. Naqvi S. H.,
    3. Razzaq R. A.,
    4. Farooqui B. J.
    Multiple drug resistant typhoid in children: presentation and clinical features. Rev. Infect. Dis. 13 1991 832 836
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    1. Bhutta Z. A.
    Impact of age and drug resistance on mortality in typhoid fever. Arch. Dis. Child. 75 1996 214 217
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Bhutta Z. A.
    Therapeutic aspects of typhoidal salmonellosis in childhood: the Karachi experience. Ann. Trop. Paediatr. 16 1996 299 306
    OpenUrlPubMedWeb of Science
  8. 8.↵
    1. Braddick M. R.,
    2. Crump B. J.,
    3. Yee M. L.
    How long should patients with Salmonella typhi or Salmonella paratyphi be followed up? A comparison of published guidelines. J. Public Health Med. 13 1991 101 107
    OpenUrlPubMed
  9. 9.↵
    1. Brown J. C.,
    2. Shanahan P. M. A.,
    3. Jesudason M. V.,
    4. Thomson C. J.,
    5. Amyes S. G. B.
    Mutations responsible for reduced susceptibility to 4-quinolones in clinical isolates of multi-resistant Salmonella typhi in India. J. Antimicrob. Chemother. 37 1996 891 900
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. Corrado M. L.,
    2. DuPont H. L.,
    3. Cooperstock M.,
    4. Fekety R.,
    5. Murray D. M.
    Evaluation of new anti-infective drugs for the treatment of typhoid fever. Clin. Infect. Dis. 15 (Suppl. I) 1992 S236 S240
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Girgis N.,
    2. Sultan I. Y.,
    3. Hammad O.,
    4. Farid Z.
    Comparison of the efficacy, safety and cost of cefixime, ceftriaxone and aztreonam in the treatment of multidrug-resistant Salmonella typhi septicemia in children. Pediatr. Infect. Dis. J. 14 1995 603 605
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    1. Gulati S.,
    2. Marwaha R. K.,
    3. Singhi S.,
    4. Ayyagari A.,
    5. Kumar L.
    Third generation cephalosporins in multi-drug resistant typhoid fever. Indian Pediatr. 29 1992 513 516
    OpenUrlPubMed
  13. 13.
    1. Gupta A.
    Multidrug-resistant typhoid fever in children: epidemiology and therapeutic approach. Pediatr. Infect. Dis. J. 13 1994 134 140
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    1. Islam A.,
    2. Butler T.,
    3. Kabir I.,
    4. Alam N. H.
    Treatment of typhoid fever with ceftriaxone for 5 days or chloramphenicol for 14 days: a randomized clinical trial. Antimicrob. Agents Chemother. 37 1993 1572 1575
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Islam A.,
    2. Butler T.,
    3. Nath S. K.,
    4. Alam N. H.,
    5. Stoeckel K.,
    6. Houser H. B.,
    7. Smith A. L.
    Randomized treatment of patients with typhoid fever by using ceftriaxone or chloramphenicol. J. Infect. Dis. 158 1988 742 747
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    1. Ivanoff B.,
    2. Levine M. M.,
    3. Lambert P. H.
    Vaccination against typhoid fever: present status. Bull. W. H. O. 72 1994 957 971
    OpenUrlPubMedWeb of Science
  17. 17.↵
    1. Lasserre R.,
    2. Sangalang R. P.,
    3. Santiago L.
    Three-day treatment of typhoid fever with two different doses of ceftriaxone, compared to 14-day therapy with chloramphenicol: a randomized trial. J. Antimicrob. Chemother. 28 1991 765 772
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    1. Mishra S.,
    2. Patwari A. K.,
    3. Anand V. K.,
    4. Pillai P. K.,
    5. Aneja S.,
    6. Chandra J.,
    7. Sharma D.
    A clinical profile of multidrug resistant typhoid fever. Indian Pediatr. 28 1991 1171 1174
    OpenUrlPubMed
  19. 19.↵
    1. Naqvi S. H.,
    2. Bhutta Z. A.,
    3. Farooqui B. J.
    Therapy of multidrug resistant typhoid in 58 children. Scand. J. Infect. Dis. 24 1992 175 179
    OpenUrlPubMedWeb of Science
  20. 20.↵
    1. Pocock S. P.
    Clinical trials: a practical approach 1983 123 141 Wiley Chichester, United Kingdom
  21. 21.↵
    1. Rowe B.,
    2. Ward L. R.,
    3. Threlfall E. J.
    Multidrug-resistant Salmonella typhi: a worldwide epidemic. Clin. Infect. Dis. 24 (Suppl. 1) 1997 S106 S109
    OpenUrl
  22. 22.↵
    1. Smith M. D.,
    2. Duong N. M.,
    3. Hoa N. T. T.,
    4. Wain J.,
    5. Ha H. D.,
    6. Diep T. S.,
    7. Day N. P. J.,
    8. Hien T. T.,
    9. White N. J.
    Comparison of ofloxacin and ceftriaxone for short-course treatment of enteric fever. Antimicrob. Agents Chemother. 38 1994 1716 1720
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Thong K. L.,
    2. Puthucheary S.,
    3. Yassin R. M.,
    4. Sudarmono P.,
    5. Padmidewi M.,
    6. Soewandojo E.,
    7. Handojo I.,
    8. Sarasombath S.,
    9. Pang T.
    Analysis of Salmonella typhi isolates from Southeast Asia by pulsed-field gel electrophoresis. J. Clin. Microbiol. 33 1995 1938 1941
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Wain J.,
    2. Diep T. S.,
    3. Ho V. A.,
    4. Walsh A. M.,
    5. Hao N. T. T.,
    6. Parry C.,
    7. White N. J.
    Quantitation of bacteria in blood of typhoid fever patients and relationship between counts and clinical features, transmissibility, and antibiotic resistance. J. Clin. Microbiol. 36 1998 1683 1687
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Wain J.,
    2. Hoa N. T. T.,
    3. Chinh N. T.,
    4. Vinh H.,
    5. Everett M. J.,
    6. Diep T. S.,
    7. Day N. P. J.,
    8. Solomon T.,
    9. White N. J.,
    10. Piddock L. J. V.,
    11. Parry C. M.
    Quinolone-resistant Salmonella typhi in Vietnam: molecular basis of resistance and clinical response to treatment. Clin. Infect. Dis. 25 1997 1404 1410
    OpenUrlCrossRefPubMedWeb of Science
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Failure of Short-Course Ceftriaxone Chemotherapy for Multidrug-Resistant Typhoid Fever in Children: a Randomized Controlled Trial in Pakistan
Zulfiqar A. Bhutta, Iqtidar A. Khan, Mamoon Shadmani
Antimicrobial Agents and Chemotherapy Feb 2000, 44 (2) 450-452; DOI: 10.1128/AAC.44.2.450-452.2000

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Failure of Short-Course Ceftriaxone Chemotherapy for Multidrug-Resistant Typhoid Fever in Children: a Randomized Controlled Trial in Pakistan
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Failure of Short-Course Ceftriaxone Chemotherapy for Multidrug-Resistant Typhoid Fever in Children: a Randomized Controlled Trial in Pakistan
Zulfiqar A. Bhutta, Iqtidar A. Khan, Mamoon Shadmani
Antimicrobial Agents and Chemotherapy Feb 2000, 44 (2) 450-452; DOI: 10.1128/AAC.44.2.450-452.2000
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

ceftriaxone
cephalosporins
typhoid fever

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596